-
Merck & Co.’s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan
•
US-based giant Merck & Co., Inc. (NYSE: MRK) announced receiving approval from the Hainan Medical Products Administration for its Winrevair (sotatercept-csrk) to be imported by Shanghai Ruijin Hospital’s Hainan subsidiary. This approval is significant as it provides a new treatment option for patients with pulmonary arterial hypertension (PAH) in China.…
-
CANbridge Pharmaceuticals Doses First Patient in CAN108 Biliary Atresia Study
•
China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the first patient has been dosed in the Phase II EMBARK study of CAN108 (maralixibat) for biliary atresia (BA). The global, multi-center, randomized, controlled trial aims to enroll 72 patients, including 20 in China, to evaluate the drug’s efficacy…
-
Pfizer’s Hympavzi (Marstacimab) Launched in China’s Boao Lecheng Pilot Zone for Hemophilia
•
Pfizer Inc. (NYSE: PFE) announced the implementation of its hemophilia therapy Hympavzi (marstacimab) in China’s Boao Lecheng Medical Tourism Pilot Zone. The drug, approved in the U.S. and European Union, is the first innovative therapy to be administered subcutaneously once weekly via a pre-filled injection pen for hemophilia A and…
-
Hainan Unveils Biomedical New Technology Policy to Boost Medical Innovation
•
In-Depth Analysis and Orientation Guide for Hainan’s Biomedical New Technology PolicyThe Hainan Provincial Health Commission, Medical Products Administration, and Boao Lecheng International Medical Tourism Pilot Zone Management Bureau have jointly released the “Implementation Measures for Biomedical New Technology Translation and Application in the Boao Lecheng International Medical Tourism Pilot Zone…
-
Boao Airport Customs Releases First Batch of Modulen IBD for Crohn’s Disease Management
•
The Boao Airport Customs under Haikou Customs has released the first batch of 96 pieces of Modulen IBD, a nutritionally complete powdered feed. This product is for the dietary management of people with Crohn’s Disease. The release indicates the implementation of a policy. The policy allows designated medical institutions within…
-
Hainan Boao Lecheng Pilot Zone Implements Baclofen Intrathecal Therapy
•
The Hainan Boao Lecheng Pilot Zone Management Bureau announced the implementation of Baclofen Intrathecal Sintetica, a special treatment for severe spasms, at the Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine and Hainan Boao Research Hospital. This therapy is suitable for patients with severe spinal cord-derived chronic spasticity (related…
-
Sanofi’s Sarclisa Gains NMPA Approval for Multiple Myeloma Treatment in China
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its Sarclisa (isatuximab) in combination with pomalidomide plus dexamethasone. This approval is for the treatment of adult patients with multiple myeloma who have previously received at least first-line…
-
Hainan Free Trade Port Gets Green Light for Temporary Import of Special Medical Foods
•
The State Administration for Market Regulation (SAMR) in China has given its approval in principle to the Interim Regulations on the Management of Temporary Import of Small amounts of Special Medical Food and Moderate Health Food into Hainan Free Trade Port by the People’s Government of Hainan Province. This move…
-
Hainan Boao Lecheng and Sanofi Partner with Paris-Saclay Cancer Cluster for Advanced Cancer Treatments
•
The Hainan Boao Lecheng International Medical Tourism Pilot Zone, in collaboration with France’s major Sanofi’s (NASDAQ: SNY) China unit and the Paris-Saclay Cancer Cluster (PSCC), has established a tripartite collaboration aimed at advancing healthcare solutions. This partnership is designed to combine the strengths of each organization to enhance the treatment…
-
Servier’s Vorasidenib Approved in Boao Lecheng Medical Zone for Diffuse Gliomas
•
French pharmaceutical company Servier’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, has been granted approval for use in the Boao Lecheng medical tourism pilot zone as a clinically urgently needed import drug. This approval comes in response to the pressing clinical needs for treatments targeting diffuse…
-
China’s Hainan Free Trade Port Implements ‘Zero Tax’ on Medical Imports for Designated Entities
•
In a joint effort to bolster healthcare services, China’s Ministry of Finance, National Health Commission (NHC), General Administration of Customs, State Taxation Administration, and National Medical Products Administration (NMPA) have announced a “zero tax” policy on drugs and medical devices imported through the Hainan Free Trade Port. The initiative targets…
-
Former Hainan Medical University President Li Jingquan Expelled for Serious Disciplinary Violations
•
Hainan’s disciplinary inspection committee has announced the expulsion of Li Jingquan, the former president of the First Affiliated Hospital of Hainan Medical University, from the Communist Party and public office due to serious violations of discipline and law. Li was found to have committed multiple infractions, including accepting gifts and…
-
Israeli Hair Transplant Innovator Hairstetics Launches First Procedure in Asia at Hainan Hospital
•
Hairstetics, an Israeli innovator in the non-absorbable polyamide hair transplant sector, has achieved a milestone with the implementation of its system at Hainan Boao LuYi Hospital, marking the first use case in Asia. The company’s cutting-edge technology addresses the complex and often slow-progressing condition of female androgenetic alopecia, a disease…
-
Roche’s Alzheimer’s Disease Diagnostic Kits Gain Approval in Hainan, Set for Use in Shanghai Ruijin Hospital
•
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has received approval from the Hainan Medical Products Administration for its suite of Alzheimer’s disease (AD) cerebrospinal fluid diagnostic kits. The approved products include Elecsys β-Amyloid (1-42) CSF II, Elecsys Phospho Tau (181P) CSF, Elecsys Total Tau CSF detection reagents, along with…
-
Beijing Launches Bio-Park: A New Hub for International Pharmaceutical Innovation
•
Beijing has unveiled an ambitious plan to construct Bio-Park, a state-of-the-art international pharmaceutical innovation park located in Beijing E-Town, during the Boao Forum for Asia. The initiative aims to establish a hub for high-energy innovation resources, support the development of high-value innovative products, and foster an efficient innovation ecosystem. Bio…
-
Shanghai Ruijin Hospital’s Hainan Subsidiary Adopts ANI Pharmaceuticals’ Veregen for HPV Treatment
•
ANI Pharmaceuticals’ Veregen, a topical ointment derived from green tea extract (catechins), has been implemented by Shanghai Ruijin Hospital’s Hainan subsidiary. Marking a significant step for the botanical drug in China, Veregen is the first such drug approved by the US FDA since 1962 and is already in use across…
-
Eisai’s Next-Gen SERD, Orserdu, Begins Real-World Study in Shanghai Ruijin Hospital’s Hainan Subsidiary
•
Shanghai Ruijin Hospital’s Hainan subsidiary has initiated a real-world study for Orserdu (elacestrant), a next-generation selective estrogen receptor degrader (SERD) originally developed by Eisai (TYO: 4523). The drug was transferred to Radius Health for global development back in 2006. In a strategic move in July 2020, the Menarini Group, based…
-
HOB Biotech Receives NMPA Approval for Clinical Trials of MM09 Sublingual Spray
•
Jiangsu-based HOB Biotech Group Corp., Ltd (SHA: 688656) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its MM09 sublingual spray. The product is intended to target indications such as mild to moderate asthma and allergic rhinitis/nasal conjunctivitis, with a focus on…
-
Eslicarbazepine Makes First Appearance in China at Sichuan University’s West China Lecheng Hospital
•
Eslicarbazepine, a voltage-gated sodium channel blocker, co-developed by Bial-Portela, Eisai, and Sumitomo Pharma, was first prescribed at the West China Lecheng Hospital of Sichuan University late last month. This epilepsy therapy marks the first special novel drug program implemented through the “first pilot, first trial” policy of the Boao Lecheng…
-
Boao Lecheng Approves Use of Sanofi’s Tzield as First-Line Therapy for Type 1 Diabetes Delay
•
Tzield (teplizumab), recognized as the world’s first and only targeted therapy for delaying the onset of type 1 diabetes, has received approval for use in the Boao Lecheng medical tourism pilot zone as a clinically urgently needed import drug. Developed by French pharmaceutical giant Sanofi, Tzield is indicated for use…
